Daily Stock List
Ensurge, Inc. (ESGI)
Today we are highlighting Ensurge, Inc. (ESGI), here at the QualityStocks Daily Newsletter.
Ensurge, Inc. focuses on developing and mining gold properties in Brazil and Guyana. Their main focus is to bring capital and technology to existing mining operations. This is to recover gold from existing tailings ponds, improve recoveries of existing milling operations and improve mining operations in exchange for an interest in these operations. Ensurge has their headquarters in Miami, Florida.
The research and investigation of mining opportunities is on-going for the Company. Concerning the Suriname Mining Project, on May 8, 2012, Ensurge issued a press release stating that they entered into a Heads of Agreement with Amery Trading, LLC to mine gold in Suriname. Ensurge will provide capital and technology to the project. Amery will provide access to 7,500 hectares in Sara Creek, Suriname.
Ensurge will recover all capital costs advanced on the project from 50 percent of net cash flow, with the remainder of the net cash flow to be split equally between the two parties. Ensurge will provide test equipment for the project. This is to determine the most favorable equipment for the geologic environment at concession. Ensurge will determine to move forward with the project or not, based on the results of the test program.
Concerning the Brazil Mining Project, on June 13, 2012, Ensurge entered into a Definitive Agreement with Metais Juara LTDA, of Pocone, Mato Grosso, Brazil. With this Agreement, Ensurge will provide technology and the capital equipment necessary to expand gold production and in return will receive an in-kind royalty payment.
As part of this Agreement, Ensurge is required to make an initial payment of four million Brazilian Reals (R$4,000,000), which is approximately US $1,968,659 based on the reported exchange rate as of July 18, 2012. This is to be paid within 90 business days from the date of signing the Agreement. In return for the payment, Ensurge will be entitled to a top line royalty payment of 17 percent of daily gold production, delivered in-kind as Dore.
Ensurge will build a new gold recovery mill to bring new technology to the current process, which is expected to increase the rate of gold recovery. The new mill will process approximately 400 tons of ore daily, with the expectation of increasing gold recovery to more than 50 percent. The expectation is that the construction of the new mill will be completed within 12 months from the initial ordering of equipment. Once the mill is completed and running as expected, the royalty payment will be increased to 41 percent. The mill and its equipment will belong to Ensurge.
Ensurge, Inc. (ESGI), closed on Thursday at $0.2390, up 69.50%, on 10,107 volume with 5 trades. The average volume for the last 60 days is 9,791 and the stock's 52-week low/high is $0.14/$6.85.
Northland Resources S.A. (NAU.TO)
Today we are highlighting Northland Resources S.A. (NAU.TO), here at the QualityStocks Daily Newsletter.
Northland Resources S.A. is a development-stage mining company that lists on the Toronto Stock Exchange. The Company has a portfolio of iron ore projects in northern Sweden and Finland. Northland is an international mining enterprise, emerging as a major European iron ore concentrate producer. The Company is in the business of acquiring, exploring and evaluating Mineral Resource properties, and either developing, joint venturing or disposing of the properties when their evaluation is completed. Northland Resources S.A. is based in Luxembourg.
Northland Resources is developing two principal projects. One is the Kaunisvaara iron ore concentrate project in Sweden. The other is the Hannukainen IOCG project in Finland. The two projects are within the Pajala Shear Zone, which is approximately 250 km long and 10 km wide, between northern Sweden and Finland.
Their Kaunisvaara Project will initially exploit two magnetite iron ore deposits. The process will yield a high-grade, high-quality magnetite iron concentrate. The construction of the Kaunisvaara project in Sweden is well underway. The expectation is that mining will start in the fourth quarter of this year. Northland Resources has entered into off-take contracts for the entire production from Kaunisvaara over the next seven to ten years.
Additionally, the Company is preparing a Definitive Feasibility Study (DFS) for their Hannukainen Iron Oxide Copper Gold (IOCG) Project in Kolari, northern Finland. They are also doing this for their Pellivuoma deposit 15 km from the Kaunisvaara process plant.
Earlier this month, Northland Resources announced their financial results for the second quarter ended June 30, 2012. The President and CEO of Northland Resources S.A., Mr. Karl-Axel Waplan, commented on the report for the second quarter of 2012:
"Construction of the Kaunisvaara project continued to advance according to the schedule during the second quarter, and we are confident that the Company will be able to start the production of a high-grade, high quality iron concentrate at the end of this year.”
Northland Resources S.A. (NAU.TO), closed on Thursday at $0.62, up 5.08%, on 787,230 volume. The stock's 52-week low/high is $0.56/$2.05.
Providence Resources, Inc. (PVRS)
Today we are highlighting Providence Resources, Inc. (PVRS), here at the QualityStocks Daily Newsletter.
Providence Resources, Inc. is a development stage company that lists on the OTC Bulletin Board. The Company engages in the acquisition, exploration, and development of oil and gas properties in Texas. They engage in exploration activities for the recovery of oil or natural gas products from the Ellenberger carbonate, Strawn carbonate, and Pennsylvanian-Wolfcamp sandstone reservoirs underlying approximately 13,341 gross acres of oil and gas leases in Val Verde County, Texas. Providence Resources has their headquarters in Austin, Texas.
During the six month period ended June 30, 2012, the Company was involved in looking for prospective financing or Joint Venture (JV) partners to fund the completion of the Val Verde County wells. They were also involved in procuring assistance to remediate the Carson 12-1 site. In addition, they were involved in satisfying continuous public disclosure requirements.
Providence Resources’ intention is to complete their Carson 10-1 and Carson 12-1 wells in Val Verde County, Texas. Over the next twelve months (subject to the availability of financing) they plan to do this work, and they may test the Strawn formation. The Company’s efforts to complete the wells to date and the testing of the Strawn formation have been delayed pending the receipt of financing commitments.
Their development of the Val Verde County leases going forward will be dependent on the Carson completion results. Reentry and completion of the existing well bores will require $4,000,000 in funding.
As pertains to their results of operations, Providence Resources, for the period from re-entering the current exploration stage on October 1, 2006, or inception, until June 30, 2012, incurred net losses of $56,228,110. Net losses for the three months ended June 30, 2012 were $438,791. This is in comparison to $1,055,396 for the three months ended June 30, 2011. Net losses for the six months ended June 30, 2012 were $843,762. This is in comparison to $1,562,886 for the six months ended June 30, 2011.
Providence Resources, Inc. (PVRS), closed on Thursday at $0.05, up 25.00%, on 3,333 volume with 2 trades. The average volume for the last 60 days is 1,971 and the stock's 52-week low/high is $0.021/$0.54.
Dacha Strategic Metals, Inc. (DSM.V)
ItsAllBull.net reported previously on Dacha Strategic Metals, Inc. (DSM.V), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
Dacha Strategic Metals, Inc. is an investment company that lists on the TSX Venture Exchange. The Company also lists on the OTCQX exchange under the symbol "DCHAF". Dacha focuses on the acquisition, storage and trading of strategic metals with a primary focus on Rare Earth Elements. The Company has their headquarters in Toronto, Ontario. They also have a China office in Beijing.
Dacha Strategic Metals is in the unique position of holding a commercial stockpile of Physical Rare Earth Elements. The Rare Earths comprise 15 elements known as the Lanthanides in the Periodic Table. Two other elements are also tied in with Rare Earths, Scandium and Yttrium. Rare Earth elements never appear on their own and always in deposits that contain all 15 elements in various percentages.
The Company’s main goal is to achieve, by way of their wholly-owned subsidiaries, long-term capital appreciation through the buying, holding and selling of Strategic Minerals, particularly, Rare Earth Elements. They are working to achieve this goal through investing in difficult to access markets by establishing trading relationships and purchasing stockpiles of Strategic Minerals.
Last week, Dacha Strategic Metals announced that they released their financial results for the quarter ended June 30, 2012. The Company reported net earnings of US$(16.7) million or US$(0.22) cents per basic share for the quarter ended June 30, 2012, from total revenue of US$(16.3) million (US$(16.3) million from the loss on their metal investments). For the quarter ended June 30, 2011, Dacha reported net earnings of US$57.8 million or US$0.79 per basic share from total revenues of US$60.3 million (US$61.6 million from gain on their metals investments, US$(1.4) million from loss on their security investments).
As of June 30, 2012, their metals inventory, which has a cost basis of US$19.6 million, had an estimated market value of US$63.4 million. During the quarter then ended, Dacha executed trades of US$5.1 million for a realized pre-tax profit of approximately US$4.1.
As at June 30, 2012, Dacha had cash of approximately US$3.1 million, for a total of US$66.5 million, or US$0.88 cents per basic share, based on 75.1 million shares outstanding, or US$0.80 cents per share on a fully diluted basis of 93.9 million shares outstanding.
Dacha Strategic Metals, Inc. (DSM.V), closed on Thursday at $0.52, up 4.00%, on 1,467,660 volume with 5 trades. The stock's 52-week low/high is $0.33/$0.96.
DARA BioSciences, Inc. (DARA)
PennyInvest, PennyStockVille, MadPennyStocks, StockEgg, BullRally, StockRich, HotOTC, CoolPennyStocks, OTCPicks, and TaglichBrothers reported on DARA BioSciences, Inc. (DARA), and we highlight the Company, here at the QualityStocks Daily Newsletter.
DARA BioSciences, Inc. is a specialty pharmaceutical company whose shares trade on the NASDAQ Capital Market. The Company focuses on the development and commercialization of oncology treatment and supportive care products. DARA increased their focus in oncology by way of their January 2012 acquisition of Oncogenerix, Inc., which holds the exclusive U.S. marketing rights to Soltamox®. DARA BioSciences has their corporate headquarters in Raleigh, North Carolina.
DARA’s Soltamox® is a novel oral liquid formulation of tamoxifen citrate that is extensively used in the treatment and prevention of breast cancer. Soltamox® is the only Food and Drug Administration (FDA) approved oral liquid version of tamoxifen citrate. It fulfills an important clinical need for patients who cannot tolerate existing solid tablet formulations of the drug.
The Company’s intention is to start marketing Soltamox® in the United States later this year. Moreover, in June 2012, DARA launched their first product called Bionect®. This is a topical treatment for skin irritation and burns associated with radiation therapy.
Before acquiring Oncogenerix, DARA BioSciences was concentrating on the development of a cancer-support therapeutic compound, KRN5500, for the treatment of neuropathic pain in patients with cancer. The Company believes this product is an excellent fit with their strategic oncology focus. It has successfully completed a Phase IIa study, and has received designation as a Fast Track Drug by the FDA.
DARA is working with the National Cancer Institute (NCI) to design an additional clinical trial under joint DARA-NCI sponsorship. This is while considering further Phase 2 development. DARA BioSciences’ pipeline also includes DB959. This is a novel, non-TZD dual delta/gamma, PPAR agonist for the treatment of type 2 diabetes and dyslipidemia. The Company has completed Phase I testing of DB959. DARA is currently pursuing opportunities to out-license this product. Furthermore, they also have the rights to other PPAR and DPPIV-inhibitor compounds for which they intend to seek out-licensing or partnering opportunities.
Last week, DARA BioSciences announced the appointment of Mr. Timothy J. Heady to the DARA Board of Directors. The appointment is the second new board member the Company has announced over the past two months. This brings the total number of Directors to six.
Mr. Heady retired in 2011 as CEO of UnitedHealthcare Pharmacy, a unit of UnitedHealthcare (UNH) representing more than $11 Billion in yearly prescription drug spending.
DARA BioSciences, Inc. (DARA), closed on Thursday at $0.76, down 7.54%, on 272,908 volume with 406 trades. The average volume for the last 60 days is 71,386 and the stock's 52-week low/high is $0.6151/$2.77.
Synthesis Energy Systems, Inc. (SYMX)
PennyTrader Publisher, SmallCapVoice, Greenbackers, and Momentum Traders reported earlier on Synthesis Energy Systems, Inc. (SYMX), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Synthesis Energy Systems, Inc. is a worldwide energy and gasification technology company. The Company provides technology, equipment and engineering services for the conversion of low rank, low cost coal and biomass feedstocks into energy and chemical products. Founded in 2003, Synthesis lists on the NASDAQ Global Market. Currently, the Company has offices in Houston, Texas, and Shanghai, China.
Synthesis Energy Systems’ corporate strategy is to create value by providing technology and equipment in regions where low rank coals and biomass feedstocks can be profitably converted into high value products via their proprietary U-GAS® fluidized bed gasification technology. The Company licenses this technology from the Gas Technology Institute.
U-GAS® gasifies coal cost effectively, without many of the harmful emissions typically associated with coal combustion plants. A primary advantage of U-GAS® relative to other gasification technologies are greater fuel flexibility provided by the ability of the Company to use all ranks of coal (including low rank, high ash and high moisture coals, which are significantly cheaper than higher grade coals), many coal waste products, and biomass feed stocks. Primary advantages also include the ability of Synthesis to operate efficiently on a smaller scale. This enables the faster construction of plants, at a lower capital cost, and, in a number of cases, closer to coal sources.
Last week, Synthesis Energy Systems announced that the syngas production facility for their Yima Joint Venture coal-to-methanol project in Henan Province, China, completed a test run of the first of three gasifiers currently under commissioning. During the present commissioning phase, each of the three gasifiers will be operated under an array of test conditions to vet the gasifier and support systems to prepare the facility for commercial operation.
This week, the Company announced that Mr. Robert W. Rigdon, President & CEO, will present at the Rodman & Renshaw Annual Global Investment Conference. This Conference will take place from September 9-11, 2012 at the Waldorf Astoria Hotel in New York City. Mr. Rigdon's presentation will be webcast via the Company's website at www.synthesisenergy.com on Tuesday, September 11, beginning at 11:40 a.m. Eastern Time (8:40 a.m. Pacific Time).
Synthesis Energy Systems, Inc. (SYMX), closed on Thursday at $1.13, up 2.73%, on 159,798 volume with 66 trades. The average volume for the last 60 days is 50,071 and the stock's 52-week low/high is $0.755/$1.88.
Stratus Media Group, Inc. (SMDI)
Proactivecrg, SmallCapVoice, Outcast Traders, OTCReporter, StockEgg, Penny Invest, Stock Rich, and CoolPennyStocks reported on Stratus Media Group, Inc. (SMDI), and we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Stratus Media Group, Inc. is an owner, operator, developer, producer, and marketer of live entertainment events. The Company also owns Stratus White, a new standard in personal lifestyle and card services for the global affluent. Stratus lists on the OTC Bulletin Board. The Company is based in Santa Barbara, California, with offices in Los Angeles, California; New York City, New York; Geneva, Switzerland; and Perugia, Italy.
The Company’s Stratus White is available by invitation only. Stratus White is a discreet, elite member & partner community. It provides exclusive and premier service access across the luxury product & travel, social, sporting, cultural and philanthropic areas of life. This includes events and experiences. The business plan of Stratus Media Group is to operate the Stratus White program and to own and realize all available event revenue rights from tickets/admissions, corporate sponsorship, television, print, radio, Internet, merchandising, and hospitality.
The objective of the Company’s management (with additional funding) is to build a profitable business by implementing an aggressive acquisition growth plan to acquire quality companies, build corporate infrastructure, and increase organic growth. The plan is to take advantage of operational efficiencies across an expanded portfolio of events to reduce costs and increase revenues. Stratus Media Group's management is currently reviewing all of the Company's existing businesses to determine which businesses to activate and when, depending on the availability of capital.
Stratus plans to use a "roll up" strategy, targeting sports and live entertainment events and companies that are independently owned and operated or being divested by larger companies with the plan to aggregate them into one large leading live entertainment company.
Assuming the availability of capital, Stratus is targeting acquisitions of event properties. Their objective is to aggressively build-up a critical mass of events, venues and companies that allow for many cross-event synergies.
At the end of June, Stratus Media Group announced that Mr. Jerold Rubinstein was appointed Chief Executive Officer and Chairman of the Board of Stratus Media Group and their subsidiary ProElite, Inc. (OTC Pink: PELE). Mr. Rubinstein replaces Mr. Paul Feller, who will remain a consultant to the Company. Mr. Rubinstein has been a member of the Board of Directors of Stratus since March of 2011. He has been Chairman of the Audit Committee since that time.
Stratus Media Group, Inc. (SMDI), closed on Thursday at $0.35, down 2.51%, on 65,905 volume with 24 trades. The average volume for the last 60 days is 34,092 and the stock's 52-week low/high is $0.29/$0.83.
Canadian Zinc Corp. (CZICF)
HotStockChat, M2 Communications, and FeedBlitz reported previously on Canadian Zinc Corp. (CZICF), and we highlight the Company, here at the QualityStocks Daily Newsletter.
Canadian Zinc Corp. is a junior exploration and development company headquartered in Vancouver, British Columbia. The Company also has offices in Toronto, Ontario, and Fort Simpson, Northwest Territories. The Company’s chief project is the Prairie Creek Zinc, Silver, Lead Mine in the Northwest Territories. Founded in 1965, Canadian Zinc trades on the OTCBB (CZICF), on the Toronto Stock Exchnage under the symbol “CZN.TO”, and under the symbol "SAS" on the Frankfurt Exchange.
The Company’s long-term objective is to bring the 100 percent-owned Prairie Creek Mine in the Mackenzie Mountains of the Northwest Territories into production as soon as is feasible. The Prairie Creek Mine has a Measured and Indicated resource of 5.43 million tonnes at a grade of 10.8 percent Zn and 10.2 percent Pb with 160 g/t Ag per tonne and an Inferred resource of 6.24 million tonnes at a grade of 14.5 percent Zn and 11.5 percent Pb with 229 g/t Ag per tonne.
Canadian Zinc acquired a 100 percent interest in the project in 1993. Since that time they have been expanding the resource and re-permitting the operation. In 2006 and 2007, they carried out major programs at Prairie Creek. The Company holds permits for the exploration and development of the Prairie Creek Property. However, they do not have all the permits necessary to operate the mine. They have applied to the Mackenzie Valley Land and Water Board for permits that will allow the operation of the mine. Canadian Zinc has entered into several Environmental Assessments for permitting.
Canadian Zinc presently holds 12.57 million shares of Vatukoula Gold Mines plc (VGM). This represents approximately 13 percent of VGM's issued share capital. VGM is a UK company listed on AIM (part of the London Stock Exchange), which currently owns and operates the Vatukoula Gold Mine located in Fiji.
Earlier this month, Canadian Zinc announced their financial results for the three and six month periods ended June 30, 2012. For the three and six month periods ended June 30, 2012, they reported a net loss and comprehensive loss of $9,423,000 and $11,955,000 respectively. This is in comparison to a net loss and comprehensive loss of $10,307,000 and $24,551,000 for the same periods respectively ending June 30, 2011. At June 30, 2012, they had a positive working capital balance of $17,710,000 including cash and cash equivalents of $914,000, short term investments of $12,101,000 and marketable securities of $5,677,000 (for a total of $18,692,000).
This week, The Government of the Northwest Territories (GNWT) announced that they continue to advance their co-operation with Canadian Zinc to further the August 2011 Socio-Economic Agreement between GNWT and Canadian Zinc with regard to the development of the Prairie Creek Mine. Following the visit to Prairie Creek, Canadian Zinc and the GNWT Department of Transportation signed a Collaboration Agreement. This Agreement is to ensure effective co-operation related to the public transportation infrastructure that will support the Prairie Creek Mine project.
Canadian Zinc Corp. (CZICF), closed on Thursday at $0.4620, down 11.66%, on 173,035 volume with 45 trades. The average volume for the last 60 days is 24,035 and the stock's 52-week low/high is $0.3336/$0.9002.
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.25, off by 1.96%, on 260,760 volume with 39 trades. The stock’s average daily volume over the past 60 days is 42,076, and its 52-week low/high is $0.21/$1.00.
International Stem Cell Corp. announced that the Company will attend and present at two key investor conferences next month, including the Wall Street Analyst Forum Investor Conference in Boston on September 7 and the massive Rodman & Renshaw Annual Global Investment Conference on September 10, showcasing the company’s vast expertise in therapeutic applications for human parthenogenetic stem cells, as well as developments in the commercialization of cell-based research and cosmetic products.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp to Participate in Upcoming Investor Conferences
International Stem Cell Corp to Present at the Southern California Investor Conference on August 30, 2012
SmallCapVoice Announces a New Audio Interview With Dr. Simon Craw, Executive Vice President of International Stem Cell Corporation
Longhai Steel, Inc. (LGHS)
The QualityStocks Daily Newsletter would like to spotlight Longhai Steel, Inc. (LGHS). Today, Longhai Steel, Inc. closed trading at $1.18, up 4.42%, on 7,416 volume with 11 trades. The stock’s average daily volume over the past 60 days is 13,901, and its 52-week low/high is $0.15/$2.26.
Longhai Steel, Inc. (LGHS) is a leading producer of high-quality steel wire in eastern China, with annual capacity of 1.5 million metric tons. Longhai's wire is manufactured into screws, nails, and wire mesh used for fencing and to reinforce concrete. Longhai recently expanded its production facility to include specialized applications such as steel wire rope, steel strand, steel belted radial tires, and steel welding rod. Longhai Steel is headquartered in Xingtai, Hebei province, the People's Republic of China.
The company's competitive advantages are its advanced production equipment and process technology, high product quality, expedited production, and close proximity to distributors and end users. Longhai Steel recently opened a second production line, which increases its overall capacity by 67% and expands its product portfolio into higher quality steel wire for specialized applications such as steel wire rope, steel strand, steel belted radial tires, and steel welding rod.
Longhai Steel's growth strategy includes capitalizing on government actions aimed at encouraging industry consolidation via the acquisition of neighboring producers at attractive valuations. The company also plans to grow organically through capacity expansion, broadening its product portfolio, improving operating efficiencies, and continued expansion of technical expertise.
China is the world's largest producer and consumer of steel and steel wires. Demand for steel products is primarily driven by spending in the construction, automotive, and infrastructure industries in China. Continued economic development in Hebei, one of the largest steel manufacturing regions in China, and neighboring provinces, and further buildout of tier 3-6 cities in China, provide tremendous medium and long term opportunities for Longhai Steel. Disclaimer
Longhai Steel, Inc. Company Blog
Longhai Steel, Inc. News:
Longhai Steel Completes Testing of New Steel Wire Facility
Longhai Steel Provides Q2 2012 Earnings Call Transcript; Gross Profit Up 34%, EPS up 32%
Longhai Steel Announces Strong Second Quarter 2012 Operating Results
Duma Energy Corp. (DUMA)
The QualityStocks Daily Newsletter would like to spotlight Duma Energy Corp. (DUMA). Today, Duma Energy Corp. closed trading at $1.43, even with yesterday's close, on 3,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 7,626, and its 52-week low/high is $1.50/$4.00.
Duma Energy Corp. (DUMA) is an aggressive growth company actively producing oil and gas in the domestic United States, both on and offshore. Leveraging its technical expertise, promising portfolio, and strong financial condition, the company plans to utilize domestic revenues and cash flow to fund its rapid growth through acquisition, while participating in transformational projects with the potential of providing exponential returns for shareholders.
The company's primary goal for fiscal year 2012 and beyond is to drive earnings growth. The company also aims to pursue listing on major exchange(s) to provide better visibility and liquidity to shareholders and financial partners. Already producing and generating revenue from oil and gas in Texas, Illinois, and Louisiana, Duma projects domestic production to exceed 1,000 barrels of oil equivalent per day (boepd) by the end of 2012; with 2,500 boepd projected by the end of 2013.
Duma was founded in 2005 and began trading on the OTCBB in 2009 via registration. In 2006, the company began producing from its first properties in Texas and soon after added production in Louisiana. In 2009, its new CEO Jeremy G. Driver came on board. Within one year, Mr. Driver had identified and negotiated an acquisition that would fundamentally reshape the company. This acquisition was made possible by the large direct cash investment by Mr. Driver and his family, as well as other investors.
The company uses only industry standard and time-tested technologies, and avoids unproven "resource plays" and other opportunities that are heavily dependent upon high commodity prices. Not bound by any geographical location or operational strategy, Duma's management team is focused on developing its existing portfolio while pursuing additional opportunities that provide rapid growth, leveraging growing revenue, cash flow, and reserves to accelerate its growth strategy. Disclaimer
Duma Energy Corp. Company Blog
Duma Energy Corp. News:
Duma Energy Acquires Interest in 5.3 Million-Acre African Concession
Duma Energy Enters Final Stage of Negotiations for African Concession
Duma Energy Provides Third Quarter Results and Demonstrates Positive Earnings
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.95, even with yesterday's close, on 37,881 volume with 21 trades. The stock’s average daily volume over the past 60 days is 5,154, and its 52-week low/high is $1.02/$1.87.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Announces New Channel Sales Partnership With RJ Young
GlobalWise Accepted as Member of Prestigious Organization Technology United
GlobalWise CEO to Be Featured Speaker at World Expo 2012 Conference
International Stem Cell Corp., a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products, today told investors of the conferences it will be presenting at next month.
Wall Street Analyst Forum Investor Conference
Date: Friday, September 7, 2012
Time: 10:35 am ET
Location: Omni Parker House – Boston, MA
Rodman & Renshaw Annual Global Investment Conference
Date: Monday, September 10, 2012
Time: 11:40 am ET
Location: The Waldorf Astoria Hotel, New York, NY
Investors interested in attending these conferences should contact the event organizers. To arrange a meeting with International Stem Cell’s management team, contact Mark McPartland with MZ Group via email firstname.lastname@example.org or phone 1-212-301-7130.
Additional information of the investor presentations will be available on the investor relations section of the company’s website atwww.internationalstemcell.com
Avatar Ventures, an emerging provider of mobile services and marketing solutions for small-sized and medium-sized businesses, today announced it has launched a new business-to-consumer advertising solution targeting smartphone users that are looking for products and services on the go.
The company’s MobileCall solution is a customized mobile marketing campaign based on the Google AdWords™ advertising service that encourages potential customers to call, click, and/or visit the business of the services they’re searching for on their smartphone.
MobileCall can be customized to focus on a particular industry or location, and utilizes Google mobile search ads and Google’s ‘click to call’ features, which enable the user to instantly access and locate their desired products and services.
Avatar Ventures’ MobileCall product also provides campaign feedback such as lead alerts and 24/7 call tracking and call recording. The company believes the convenience and tailored service benefits both the business and consumer.
“With growing momentum in mobile, we are focused on helping small businesses connect with customers on their smartphones, where a Google search is often the gateway to profitable interaction,” Voltair Gomez, president of Avatar Ventures stated in the press release. “A MobileCall campaign can help drive qualified leads by instantly introducing a potential customer to products and services in a mobile-enhanced environment, giving customers the option to click to call or link to a business’s mobile Web site that has been specifically designed by Avatar to make the process simple and seamless.”
For more information visit www.avatarventurescorp.com/mobilecall
Stevia First is an early-stage agribusiness focused on the industrial scale production of the natural sweetener stevia, which is used as a zero-calorie alternative to sugar in foods and beverages. The California-based company today announced that it has entered into an exclusive and worldwide intellectual property license with the Vineland Research and Innovation Centre of Ontario, Canada, regarding compositions and methods for producing steviol and steviol glycosides through fermentation-based production methods.
Stevia First also said it has inked a separate consulting agreement with Vineland to assist with further development of the underlying intellectual property.
The production of stevia extract involves a complex extraction and purification process, which leads to higher production costs and hinders the sweetener from meeting taste and consistency standards. However, Stevia First reports that Canadian researchers at Agriculture and Agri-Food Canada (AAFC) have discovered the natural biochemical pathways involved in the production of the sweet components of the stevia leaf. Vineland currently controls intellectual property related to this technology; and leveraging this knowledge, Stevia First says it is possible to produce stevia extract through the low-cost fermentation-based technologies.
“In the stevia industry, which has grown tremendously over the past several years, there is still significant unmet demand from multinational companies for a supply chain that can consistently produce great-tasting stevia extract in large quantities,” Stevia First Corp. CEO Robert Brooke stated in the press release. “The technology we’ve licensed represents a potential solution for this need, and one that our scientific team is eager to commercialize.”
Per the licensing agreement, Stevia First obtains exclusive rights to an intellectual property portfolio derived from a patent titled, “Compositions and methods for producing steviol and steviol glycosides.”
For more information visit: www.steviafirst.com
AcelRx Pharmaceuticals announced that patents have been approved for “Bioadhesive Drug Formulations for Oral Transmucosal Delivery,” and “Bioadhesive Drug Formulations for Oral Transmucosal Delivery.” The issued patents will provide intellectual property protection for a bioadhesive tablet for oral transmucosal administration of sufentanil through January 2027. AcelRx exclusively owns both patents.
“We have made significant progress this year in establishing our intellectual property portfolio, with five issued US patents now underpinning our novel NanoTab technology,” said Richard King, AcelRx’s President and CEO. “We look forward to building on this success through emphasis on the device aspects of our technology platforms as we seek multiple avenues of protection for our proprietary pipeline of product candidates.”
The first patent provides protection in the United States for each of AcelRx’s four development programs. It also covers AcelRx’s proprietary NanoTab technology for delivering sufentanil with claims to a substantially homogenous bioadhesive tablet which adheres throughout the period of drug delivery, generates a minimal saliva response, and delivers a majority of the drug through the oral mucosa.
The second patent also covers the composition of sufentanil NanoTabs with claims to a bioadhesive tablet for sublingual administration to a subject wherein the bioadhesive material is present at between 2% and 30% by weight, and the tablet generates a minimal saliva response and minimal swallowed drug and delivers at least 55% of the sufentanil through the oral transmucosal route.
Other means to protecting the intellectual property include U.S. patents which claim both methods and compositions directed to sufentanil containing NanoTabs. There is also European patent protection which covers small-volume NanoTab dosage forms for transmucosal administration containing the opioid sufentanil and elements of AcelRx’s dispensing technology and provides patent protection of specific pharmacokinetic parameters derived from sublingual administration using the NanoTab technology. Additionally, AcelRx currently has more than 70 pending patent applications worldwide and continues to file additional new patent applications to further strengthen its market exclusivity.
AcelRx Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. AcelRx’s lead product candidate, the ARX-01 Sufentanil NanoTab PCA System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia, which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery, and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps. This product is currently in Phase 3 clinical trials. AcelRx has two additional product candidates which have completed Phase 2 clinical development and plans to initiate a Phase 2 study, pending protocol approval, for a fourth product.
For additional information about AcelRx’s clinical programs please visitwww.acelrx.com
Today's Top 3
Wall Street Resources
The QualityStocks Public Company Sponsor News